Skip to content

Comparing the efficiency and performance of AMBU AURA40 with proseal LMA

A comparative evaluation of performance of AMBU AURA40 with Proseal LMA:A randomised prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050386
Enrollment
50
Registered
2023-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: AMBU AURA40: Standardized anaesthesia protocol will be followed. Peripheral intravenous line will be secured with appropriate sized cannula. Pre-oxygenation for 3 minutes will be done w

Sponsors

Department of Anaesthesiology and Critical care
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients aged between 18-60 years of either sex of ASA grade I and II scheduled for elective surgery requiring general anaesthesia and where placement of supraglottic airway device is indicated will be included.

Exclusion criteria

Exclusion criteria: Patients having respiratory or pharyngeal pathology, mouth opening 30 kg/m², pregnancy, full stomach, suspected difficult airway will be excluded.

Design outcomes

Primary

MeasureTime frame
To compare the success rate of placement and OLP for the two devices Timepoint: Insertion time and number of attempts taken for placing the device noted.Hemodynamic changes assessed baseline,after induction,after insertion and 5 min after device placement.post op complications-immediate,after half an hour and after 1 hour

Secondary

MeasureTime frame
Time taken for placement Number of attempts Haemodynamic variation Post-operative complicationsTimepoint: Hemodynamic changes assessed baseline,after induction,after insertion and 5 min after device placement.post op complications-immediate,after half an hour and after 1 hour will be assessed for both AMBU AURA40 and Proseal LMA. Data will be compiled and appropriate statistical tests will be used to analyse the results

Countries

India

Contacts

Public ContactDr Miraarabinth

Pt.B.D. Sharma PGIMS rohtak

kiranpreet72@rediffmail.com9992249436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026